The Biospecimen Management Consortium is an industry-led consortium with the shared objective of driving sample excellence in clinical research.
Hosted by Slope, this consortium assembles founding member organizations chosen for their expertise in biospecimen lifecycle management and their commitment to challenging the status quo. The BMC openly welcomes novel ideas and suggested areas of improvement within the scope of biospecimen lifecycle management.
To raise awareness of the importance and criticality of biospecimen management, develop industry standards and best practices, and advocate for change within the clinical trial ecosystem through standardization, policy, and thought leadership.
To elevate industry-wide excellence in biospecimen management, raise the bar for data integrity and quality, enable the future of complex clinical research, and protect precious patient samples.
"
This important initiative challenges the status quo of how biospecimens are managed today, in order to ensure the success and accuracy of complex clinical trials that rely so heavily on this data and the timelines associated with it."
Identify and influence key regulations and policies impacting proper biospecimen lifecycle management.
Drive innovation at the intersection of people, process, and technology for more efficient, compliant, and higher quality trials.
Protect sample data integrity throughout the entire biospecimen lifecycle.
